TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Travere Therapeutics, Inc.
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$50.49+0.89 (+1.79%)
Close on Oct 19, 2026
- Market cap
- $4.72B
- P/E (TTM)
- –
- Dividend yield
- –
Travere Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 27 | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $525.60M | $459.09M | $410.46M | $357.40M | $305.25M | $262.58M | $226.71M | $193.08M | $166.01M | $143.34M | $127.54M | $113.44M | 88.9% | +72.2% |
| FILSPARI | $440.47M | $371.28M | $322.01M | $268.31M | $213.03M | $168.27M | $132.22M | $97.28M | $69.70M | $46.04M | $29.21M | $14.51M | 74.5% | +106.8% |
| Tiopronin products | $85.14M | $87.82M | $88.46M | $89.09M | $92.22M | $94.32M | $94.49M | $95.80M | $96.31M | $97.31M | $98.33M | $98.93M | 14.4% | -7.7% |
| License and collaboration revenue | $65.73M | $77.10M | $80.27M | $78.43M | $28.62M | $10.95M | $6.47M | $10.37M | $11.64M | $12.38M | $17.70M | $16.08M | 11.1% | +129.7% |
| Clinical Development Activity | – | – | – | – | – | – | – | – | – | – | $14.40M | – | – | – |
| Active Pharmaceutical Ingredient | – | – | – | – | – | – | – | – | – | – | $3.30M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Travere Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.